<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934696</url>
  </required_header>
  <id_info>
    <org_study_id>IM018-006</org_study_id>
    <nct_id>NCT04934696</nct_id>
  </id_info>
  <brief_title>A Study to Characterize the Pharmacokinetics of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential</brief_title>
  <official_title>A Phase 1 Study to Characterize the Effects of BMS-986166 on the Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone in Healthy Female Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the potential for a drug-drug interaction (DDI)&#xD;
      when BMS-986166 and hormonal oral contraceptives are co-administered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric means ratio of Cmax of NET</measure>
    <time_frame>Up to Day 26</time_frame>
    <description>Geometric means ratio of maximum observed plasma concentration (Cmax) of norethindrone (NET) when administered with versus without BMS-986166</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric means ratio of Cmax of EE</measure>
    <time_frame>Up to Day 26</time_frame>
    <description>Geometric means ratio of maximum observed plasma concentration (Cmax) of ethinyl estradiol (EE) when administered with versus without BMS-986166</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric means ratio of AUC(0-T) of NET</measure>
    <time_frame>Up to Day 26</time_frame>
    <description>Geometric means ratio of area under the plasma concentration-time curve from time zero to time of last quantifiable concentration for NET when administered with versus without BMS-986166</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric means ratio of AUC(0-T) of EE</measure>
    <time_frame>Up to Day 26</time_frame>
    <description>Geometric means ratio of area under the plasma concentration-time curve from time zero to time of last quantifiable concentration for EE when administered with versus without BMS-986166</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric means ratio of AUC(INF) of NET</measure>
    <time_frame>Up to Day 26</time_frame>
    <description>Geometric means ratio of area under the plasma concentration-time curve from time zero extrapolated to infinite time for NET administered with versus without BMS-986166</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric means ratio of AUC(INF) of EE</measure>
    <time_frame>Up to Day 26</time_frame>
    <description>Geometric means ratio of area under the plasma concentration-time curve from time zero extrapolated to infinite time for EE when administered with versus without BMS-986166.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of BMT-121795</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-986166</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of BMT-121795</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986166</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU) of BMT-121795</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of EE</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of NET</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal plasma elimination phase half-life (T-HALF) of EE</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-HALF of NET</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total clearance of drug from plasma after oral administration (CLT/F) of EE</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLT/F of NET</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at terminal phase (Vz/F) of EE</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F of NET</measure>
    <time_frame>Up to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>Up to Day 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in laboratory values: Hematology tests</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in laboratory values: Chemistry tests</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in laboratory values: Urinalysis</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Up to Day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to Day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Up to Day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to Day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in ECG parameters: PR interval</measure>
    <time_frame>Up to Day 27</time_frame>
    <description>PR interval is the time from the onset of the P wave to the start of the QRS complex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in ECG parameters: QRS</measure>
    <time_frame>Up to Day 27</time_frame>
    <description>QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in ECG parameters: QT interval</measure>
    <time_frame>Up to Day 27</time_frame>
    <description>The QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in ECG parameters: QTcF</measure>
    <time_frame>Up to Day 27</time_frame>
    <description>QTcF = corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with physical examination abnormalities</measure>
    <time_frame>Up to Day 27</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>BMS-986166 + Oral contraceptive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986166</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-986166 + Oral contraceptive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral contraceptive</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-986166 + Oral contraceptive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial preparation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Nonpregnant, nonlactating Women of Childbearing Potential (WOCBP) who are healthy as&#xD;
             determined by medical history, physical examination, vital signs, 12-lead ECG, and&#xD;
             clinical laboratory evaluations will be eligible to participate in the study.&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 32.0 kg/m². BMI = weight (kg)/(height[m])² for&#xD;
             participants.&#xD;
&#xD;
          -  Participant must be 18 to 45 years of age, inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant acute or chronic medical illness judged to be clinically significant&#xD;
             by the investigator and/or Sponsor Medical Monitor.&#xD;
&#xD;
          -  History of any type of heart disease, including ischemia, infarction, clinically&#xD;
             significant arrhythmias, sinus syndrome, hypertension, symptomatic orthostatic&#xD;
             hypotension, atrioventricular block of any degree, bradycardia, syncope, clinically&#xD;
             significant ECG abnormalities, or any congenital heart disease.&#xD;
&#xD;
          -  Any acute or chronic bacterial, fungal (except history of tinea pedis or ongoing&#xD;
             onychomycosis will not be exclusionary) or viral infection within the last 3 months&#xD;
             prior to screening, as well as any febrile illness or viral infection within the last&#xD;
             3 months prior to screening, as well as any febrile illness of unknown origin within&#xD;
             14 days of screening.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information</last_name>
    <phone>please email</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Ramos</last_name>
      <phone>714-252-0700</phone>
      <phone_ext>1018</phone_ext>
      <email>margarita.ramos@wcct.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/us/en/home.html</url>
    <description>BMS clinical trial education resource</description>
  </link>
  <link>
    <url>https://vivli.org/ourmember/bristol-myers-squibb/</url>
    <description>BMS clinical trial data request</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Participants</keyword>
  <keyword>BMS-986166</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

